Gilead Sciences @GileadSciences · 24 Jul 2026
#GileadNews: We received a #CHMP positive opinion for our combination regimen in PD-(L)1-positive first-line metastatic triple-negative breast cancer. If approved, patients with PD-(L)1 positive mTNBC will have a new treatment option in Europe. https://t.co/RYU4enosT1 https://t.co/Lkg9QPaRYN
3 451Views
14Likes
3Reposts
5Replies
0Quotes
1Bookmarks
Is that a lot?
2.10×vs this author's median1 647 views is typical
71Percentile for this authorof 7 recent posts
1.26×vs 10K–100K median2 747 views is typical
4.77%Reachviews ÷ followers
0.64%Engagement rateof viewers reacted